Effect of TP Chemotherapy Regimen Combined with Trastuzumab in the Treatment of HER2 Positive Breast Cancer and Its Influence on Serum Tumor Markers

YAN Xiaojie

doi:10.3969/j.issn.1672-7185.2024.05.008

Abstract：Objective To investigate the effect of TP chemotherapy regimen combined with trastuzumab in the treatment of HER2 positive breast cancer(BC),and the influence on serum tumor markers of patients.Methods A total of 106 HER2 positive BC patients who were treated in Hygeia Hospital of Shan County from June 2019 to June 2023 were selected.All patients were divided into the combined group of 53 patients who were treated with TP chemotherapy regimen combined with trastuzumab,and the control group of 53 patients who were treated with TP chemotherapy regimen alone.Compare the efficacy and incidence of adverse reactions during treatment between the two groups,as well as the levels of serum tumor markers and quality of life before and after treatment.Results After treatment,the levels of serum carcinoembryonic antigen,carbohydrate antigen 125,and carbohydrate antigen 153 were significantly lower than before treatment in both groups,and the combined group was significantly lower than the control group(P<0.05).After treatment,the scores of the functional assessment of cancer therapy-breast cancer scale were significantly higher than those before treatment in both groups,and the scores in the combined group were significantly higher than those in the control group(P<0.05).The total effective rate and the disease control rate in the combined group was 45.28%and 81.13%,which were significantly higher than the control group's 20.75%and 64.15%respectively(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For HER2 positive BC patients,TP chemotherapy regimen combined with trastuzumab has better clinical effect than TP chemotherapy regimen alone,can further reduce the level of serum tumor markers,and has good safety,which is worthy of clinical promotion.